• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

    9/22/25 8:00:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email

    CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden.

    Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property for the manufacturing of reagents used to measure these biomarkers, allowing Immunovia to purchase reagents directly from the supplier of Proteomedix.

    In return, Immunovia will make payments totaling $700,000 to Proteomedix in 2025 and 2026, as well as pay a 3% royalty on net sales of PancreaSure and any other products incorporating the licensed intellectual property from 2026 to 2032.

    "We are proud to have contributed to the development of PancreaSure and are excited to now support its manufacturing. Earlier detection of pancreatic cancer through PancreaSure gives patients real hope for better outcomes," said Beat Rheiner, PhD, CEO of Proteomedix." "At the same time, we remain focused on expanding the market penetration of our early prostate cancer detection test, Proclarix®." said Karina Fedasz, Interim CEO of Onconetix.

    About Onconetix, Inc.

    Onconetix (NASDAQ:ONCO) is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Through our acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ("EU") under the IVDR.

     For more information, visit www.onconetix.com.

    About Proclarix®

    Proclarix® is CE-certified under In Vitro Diagnostic Regulation ("IVDR") and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix® is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient's risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix® risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer. Proclarix® is included in both the European (EAU) and American (AUA) guidelines.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements (including, without limitation, the anticipated results of or proceeds from the license to Immunovia) are based on Onconetix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; risks related to Onconetix's ability to commercialize or monetize Proclarix; risks related to the Company's present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix's ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company's commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix's products; risks related to the Company's ability to obtain and maintain intellectual property protection for its current products; whether the Company will be able to maintain compliance with Nasdaq's applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company's securities; and the Company's reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix's Annual Report on Form 10-K, filed with the SEC on June 2, 2025 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Contact Information:

    Onconetix, Inc.

    201 E. Fifth Street, Suite 1900

    Cincinnati, OH 45202

    Phone: (513) 620-4101

    Investor Contact Information:

    Onconetix Investor Relations Email: [email protected] 



    Primary Logo

    Get the next $ONCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

    CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

    9/26/25 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

    CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

    9/26/25 8:15:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

    CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property

    9/22/25 8:00:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tarsh Simon acquired 39 shares and was granted 618 shares, increasing direct ownership by 65,700% to 658 units (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:27 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meier Thomas acquired 39 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:25 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Oakley Andrew John acquired 20 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:29 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    SEC Filings

    View All

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/26/25 8:45:57 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/22/25 8:37:50 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/4/25 4:05:41 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care